Nathalie is CMO at Nimbus Therapeutics. Her extensive biotech career has spanned from discovery research and target validation through early and late clinical development including multiple filings globally, medical affairs with launch and reimbursement in international markets. Prior to Nimbus she was SVP, Head of Multiple Sclerosis and Immunology Development Unit and member of the R&D Leadership Team at Biogen, where she previously held a variety of other leadership roles. Prior to Biogen, Nathalie held Medical Affairs and Clinical Research roles at Amgen. Nathalie serves as a non-executive Director on the Board of OMASS. Nathalie is a rheumatologist and trained as an M.D., Ph.D. at the University of Liège, Belgium.